Rare diseases are increasingly recognized as a global public health priority. Governments worldwide currently provide important incentives to stimulate the discovery and development of orphan drugs for the treatment of these conditions, but substantial …
William Blair analyst Andrew Brackmann said Labcorp is being aggressive in its M&A strategy, after announcing last month it would buy several of Bioreference Health’s testing businesses.
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Kinnear et al. demonstrate the ability of myosin inhibitors to restore function in pediatric hypertrophic cardiomyopathy patient and gene-edited iPSC-cardiomyocytes harboring myosin variants. From monogenic to…
★★★★★ · Non-profit organization
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM – Full Text View.
TN-201 gene therapy is being studied in the Phase 1b MyPeak-1™ clinical trial for the treatment of genetic hypertrophic cardiomyopathy caused by variations i…
